Secretome and degradome profiling shows that Kallikrein‐related peptidases 4, 5, 6, and 7 induce TGFβ‐1 signaling in ovarian cancer cells

Kallikrein‐related peptidases, in particular KLK4, 5, 6 and 7 (4–7), often have elevated expression levels in ovarian cancer. In OV‐MZ‐6 ovarian cancer cells, combined expression of KLK4–7 reduces cell adhesion and increases cell invasion and resistance to paclitaxel. The present work investigates how KLK4–7 shape the secreted proteome (“secretome”) and proteolytic profile (“degradome”) of ovarian cancer cells. The secretome comparison consistently identified >900 proteins in three replicate analyses. Expression of KLK4–7 predominantly affected the abundance of proteins involved in cell–cell communication. Among others, this includes increased levels of transforming growth factor β‐1 (TGFβ‐1). KLK4–7 co‐transfected OV‐MZ‐6 cells share prominent features of elevated TGFβ‐1 signaling, including increased abundance of neural cell adhesion molecule L1 (L1CAM). Augmented levels of TGFβ‐1 and L1CAM upon expression of KLK4–7 were corroborated in vivo by an ovarian cancer xenograft model. The degradomic analysis showed that KLK4–7 expression mostly affected cleavage sites C‐terminal to arginine, corresponding to the preference of kallikreins 4, 5 and 6. Putative kallikrein substrates include chemokines, such as growth differentiation factor 15 (GDF 15) and macrophage migration inhibitory factor (MIF). Proteolytic maturation of TGFβ‐1 was also elevated. KLK4–7 have a pronounced, yet non‐degrading impact on the secreted proteome, with a strong association between these proteases and TGFβ‐1 signaling in tumor biology.

[1]  E. Diamandis,et al.  Human tissue kallikreins: a road under construction. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[2]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[3]  L. Foster,et al.  Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products , 2010, Nature Biotechnology.

[4]  J. Clements,et al.  Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. , 2012, Gynecologic oncology.

[5]  C. Heldin,et al.  Regulation of EMT by TGFβ in cancer , 2012, FEBS letters.

[6]  E. Diamandis,et al.  Human Kallikrein 6 Degrades Extracellular Matrix Proteins and May Enhance the Metastatic Potential of Tumour Cells , 2004, Tumor Biology.

[7]  Daniela Loessner,et al.  Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. , 2010, Cancer research.

[8]  D. Katsaros,et al.  Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. , 2006, Clinical chemistry.

[9]  C. Craik,et al.  Specificity Profiling of Seven Human Tissue Kallikreins Reveals Individual Subsite Preferences* , 2006, Journal of Biological Chemistry.

[10]  S. Mok,et al.  Characterisation of human kallikrein 6/protease M expression in ovarian cancer , 2004, British Journal of Cancer.

[11]  K. Shigemasa,et al.  Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors , 2001, International Journal of Gynecologic Cancer.

[12]  Christopher M. Overall,et al.  Factor Xa subsite mapping by proteome-derived peptide libraries improved using WebPICS, a resource for proteomic identification of cleavage sites , 2011, Biological chemistry.

[13]  V. Notario,et al.  The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential , 2013, Nature Reviews Cancer.

[14]  P. Nelson,et al.  New nomenclature for the human tissue kallikrein gene family. , 2000, Clinical chemistry.

[15]  María Martín,et al.  Activities at the Universal Protein Resource (UniProt) , 2013, Nucleic Acids Res..

[16]  T. Reinheckel,et al.  Deletion of Cysteine Cathepsins B or L Yields Differential Impacts on Murine Skin Proteome and Degradome* , 2012, Molecular & Cellular Proteomics.

[17]  E. Diamandis,et al.  Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines* , 2009, Molecular & Cellular Proteomics.

[18]  K. Gevaert,et al.  Improved visualization of protein consensus sequences by iceLogo , 2009, Nature Methods.

[19]  M. Dimopoulos,et al.  Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  A. Scorilas,et al.  Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA) , 2008, Cancer science.

[21]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[22]  D. Katsaros,et al.  Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Ruedi Aebersold,et al.  Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry , 2003, Nature Biotechnology.

[24]  D. Galileo,et al.  Soluble L 1 CAM promotes breast cancer cell adhesion and migration in vitro , but not invasion , 2010 .

[25]  Dietmar W Hutmacher,et al.  A multiscale road map of cancer spheroids – incorporating experimental and mathematical modelling to understand cancer progression , 2013, Journal of Cell Science.

[26]  R. Aebersold,et al.  A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.

[27]  Manfred Schmitt,et al.  Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7 , 2008, Biological chemistry.

[28]  C. Overall,et al.  Multiplex N-terminome Analysis of MMP-2 and MMP-9 Substrate Degradomes by iTRAQ-TAILS Quantitative Proteomics* , 2010, Molecular & Cellular Proteomics.

[29]  M. Matsumura,et al.  Substrates of the prostate‐specific serine protease prostase/KLK4 defined by positional‐scanning peptide libraries , 2005, The Prostate.

[30]  Robert Burke,et al.  ProteoWizard: open source software for rapid proteomics tools development , 2008, Bioinform..

[31]  J. Keski‐Oja,et al.  Latent TGF-β Binding Proteins: Extracellular Matrix Association and Roles in TGF-β Activation , 2004 .

[32]  R. Haun,et al.  The extracellular matrix protein fibronectin is a substrate for kallikrein 7. , 2008, Biochemical and biophysical research communications.

[33]  R. Leduc,et al.  Processing of Transforming Growth Factor 1 Precursor by Human Furin Convertase (*) , 1995, The Journal of Biological Chemistry.

[34]  E. Diamandis,et al.  Human tissue kallikrein gene family: applications in cancer. , 2005, Cancer letters.

[35]  H. Samaratunga,et al.  Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  E. Diamandis,et al.  Human tissue kallikreins: physiologic roles and applications in cancer. , 2004, Molecular cancer research : MCR.

[37]  L. Madisen,et al.  Site-directed mutagenesis of glycosylation sites in the transforming growth factor-beta 1 (TGF beta 1) and TGF beta 2 (414) precursors and of cysteine residues within mature TGF beta 1: effects on secretion and bioactivity. , 1992, Molecular endocrinology.

[38]  Robertson Craig,et al.  TANDEM: matching proteins with tandem mass spectra. , 2004, Bioinformatics.

[39]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[40]  E. Diamandis,et al.  Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel , 2008, British Journal of Cancer.

[41]  G. Yousef,et al.  KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma , 2009, British Journal of Cancer.

[42]  K. Shigemasa,et al.  Increased Expression of Protease M in Ovarian Tumors , 1999, Tumor Biology.

[43]  D. Katsaros,et al.  Parallel overexpression of seven kallikrein genes in ovarian cancer. , 2003, Cancer research.

[44]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[45]  E. Diamandis,et al.  Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines , 2007, Molecular & Cellular Proteomics.

[46]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[47]  E. Diamandis,et al.  Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression* , 2005, Journal of Biological Chemistry.

[48]  M. Roett,et al.  Ovarian cancer: an overview. , 2009, American family physician.

[49]  T. Reinheckel,et al.  Contribution of cathepsin L to secretome composition and cleavage pattern of mouse embryonic fibroblasts , 2011, Biological chemistry.

[50]  Tian-Li Wang,et al.  Ovarian cancer specific kallikrein profile in effusions. , 2007, Gynecologic oncology.

[51]  Jennifer L. Harris,et al.  Defining the extended substrate specificity of kallikrein 1-related peptidases , 2007, Biological chemistry.

[52]  J. Keski‐Oja,et al.  Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. , 2004, Critical reviews in clinical laboratory sciences.

[53]  P. Altevogt,et al.  EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation. , 2012, Carcinogenesis.

[54]  Alexey I Nesvizhskii,et al.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.

[55]  R. Kreienberg,et al.  Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines , 1992, International journal of cancer.

[56]  R. Aebersold,et al.  Automated statistical analysis of protein abundance ratios from data generated by stable-isotope dilution and tandem mass spectrometry. , 2003, Analytical chemistry.

[57]  B. R. Hoffman,et al.  Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker , 2002, British Journal of Cancer.

[58]  A. Chalaris,et al.  The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin β and ADAM10 , 2012, Cellular and Molecular Life Sciences.

[59]  Erming Tian,et al.  Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy , 2004, International journal of cancer.

[60]  B. Fingleton,et al.  Systems-Level Analysis of Proteolytic Events in Increased Vascular Permeability and Complement Activation in Skin Inflammation , 2013, Science Signaling.

[61]  J. Clements,et al.  Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. , 2005, Endocrine-related cancer.

[62]  R. Aebersold,et al.  Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry , 2001, Nature Biotechnology.

[63]  Lennart Martens,et al.  DBToolkit: processing protein databases for peptide-centric proteomics , 2005, Bioinform..

[64]  Chris F. Taylor,et al.  A common open representation of mass spectrometry data and its application to proteomics research , 2004, Nature Biotechnology.

[65]  H. Broxmeyer,et al.  Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis , 2012, Nature Medicine.

[66]  C. López-Otín,et al.  Emerging roles of proteases in tumour suppression , 2007, Nature Reviews Cancer.

[67]  M. Mann,et al.  Trypsin Cleaves Exclusively C-terminal to Arginine and Lysine Residues*S , 2004, Molecular & Cellular Proteomics.

[68]  J. Shaughnessy,et al.  The role of Dickkopf-1 in bone development, homeostasis, and disease. , 2009, Blood.

[69]  G. Yousef,et al.  The human kallikrein gene family: new biomarkers for ovarian cancer. , 2009, Cancer treatment and research.

[70]  C. Flechtenmacher,et al.  Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. , 2007, Cancer research.

[71]  Robert C. Bast,et al.  Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.

[72]  G. Yousef,et al.  Tissue kallikreins: new players in normal and abnormal cell growth? , 2003, Thrombosis and Haemostasis.

[73]  Dietmar W. Hutmacher,et al.  Bioengineered 3 D platform to explore cell e ECM interactions and drug resistance of epithelial ovarian cancer cells , 2022 .

[74]  B. Davidson,et al.  Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. , 2004, Gynecologic oncology.

[75]  G. Yousef,et al.  Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. , 2003, Cancer research.

[76]  E. Diamandis,et al.  Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins , 2006, Biological chemistry.

[77]  A. Krüger,et al.  Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells , 2006, Biological chemistry.

[78]  Dietmar W. Hutmacher,et al.  Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. , 2010, Biomaterials.

[79]  The UniProt Consortium,et al.  Update on activities at the Universal Protein Resource (UniProt) in 2013 , 2012, Nucleic Acids Res..

[80]  A. Berger,et al.  Peptides of L-and D-alanine. Synthesis and optical rotations. , 1966, Biochemistry.

[81]  D. Cao,et al.  TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. , 2010, Frontiers in bioscience.

[82]  G. Yousef,et al.  Immunofluorometric Quantification of Human Kallikrein 5 Expression in Ovarian Cancer Cytosols and Its Association with Unfavorable Patient Prognosis , 2003, Tumor Biology.

[83]  W. Lau,et al.  Dickkopf-1: As a Diagnostic and Prognostic Serum Marker for Early Hepatocellular Carcinoma , 2013, The International journal of biological markers.

[84]  Jihun Lee,et al.  Activation Profiles and Regulatory Cascades of the Human Kallikrein-related Peptidases* , 2007, Journal of Biological Chemistry.

[85]  D. Katsaros,et al.  Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. , 2003, Clinical biochemistry.

[86]  John Clarke,et al.  The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells , 1999, Cancer.